Description
This prostamax nasal spray supplies Prostamax, a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Pro, abbreviated KEDP, molecular formula C20H33N5O9, molecular weight approximately 487.5 Da. It comes from the short peptide bioregulator programme at the St Petersburg Institute of Bioregulation and Gerontology, and within that framework it is associated with prostate tissue. Prostate cell biology has one methodological fork that decides what an experiment can show, and it is worth understanding before you start. Supplied for laboratory research use only.
If you arrived here from a prostate supplement search
Worth clearing up first, because the search results for this area are dominated by a different category of product entirely.
Most pages using the vocabulary of prostate health, prostate wellness and men’s health are selling botanical supplements. That category is built on saw palmetto, pygeum and occasionally bee venom, usually delivered as softgels, and marketed with phrases like all-natural, all-natural solution and natural wellness alongside promises to revitalize your prostate health or restore energy and vitality. Some of those listings also make circulatory claims, describing improved circulation or increased blood flow to the prostate.
This is not that. Prostamax is a defined synthetic tetrapeptide sold as a research chemical for in-vitro work. It contains no botanical extract, it is not a supplement, and it makes no wellness, anti-aging or longevity claim. The distinction matters commercially as well as legally: a botanical softgel and a research peptide are not competing products, they are different things sold to different buyers.
The condition vocabulary needs separating out too. Search interest around this tissue clusters on prostatitis and chronic prostatitis, on benign prostatic hyperplasia and its abbreviation BPH, and on the symptoms people associate with them, including urinary flow, frequent urination, urgency and pain relief. Those are medical conditions and symptoms. Nothing on this page addresses any of them, no claim is made about prostate issues, prostate inflammation or prostate-related concerns of any kind, and this material has no approval to treat anything. If prostate symptoms are the reason you are reading, the useful next step is a clinician rather than a research compound.
What remains, and what the rest of this page is about, is cell biology: what happens when a defined peptide meets prostate tissue models in a dish, and how to design that experiment so the answer means something.
Androgen-sensitive or androgen-independent: pick deliberately
Three prostate cell lines dominate the literature, and they are not interchangeable. The difference between them is not a detail of provenance, it is a difference in the biology they can model at all.
LNCaP expresses the androgen receptor and responds to androgens, which makes it the line for anything involving androgen signalling. It also carries a mutated androgen receptor with broadened ligand specificity, so it can respond to steroids that would not activate the wild-type receptor, and that quirk has caught out a lot of people.
PC-3 and DU145 do not express functional androgen receptor and do not respond to androgens. They are used for androgen-independent prostate biology. PC-3 is derived from a bone metastasis and DU145 from a brain metastasis, and both are aggressive, fast-growing lines with quite different characteristics from normal prostate epithelium.
The practical consequence is direct. If your question touches androgen signalling in any way, PC-3 and DU145 cannot answer it, and a null result in them is uninformative rather than negative. If your question is about androgen-independent behaviour, LNCaP is the wrong background. And all three are carcinoma lines derived from tumours rather than from a healthy prostate gland, so none of them models normal prostate epithelium. For that you need primary prostate epithelial cells or an immortalized non-tumorigenic line such as RWPE-1, which behaves very differently from the carcinoma lines and is the more appropriate choice for a compound framed around normal tissue maintenance.
That last point matters for a bioregulator specifically. The claim made for this class is about maintaining or restoring normal tissue gene expression, and testing that in an aggressive carcinoma line is testing it in the wrong biology. Running intranasal prostamax research or any cell work with this peptide in PC-3 because it grows fast is a convenience decision that quietly changes the question.
The proline, and what the sequence tells you
KEDP shares three of its four residues with Cortagen, which is Ala-Glu-Asp-Pro. Both end in proline, and proline is structurally distinctive: its side chain loops back to the backbone nitrogen, forming a ring that restricts rotation. A peptide containing proline is conformationally more rigid than its length suggests, and if these short peptides have any genuine binding specificity, that rigidity is likely part of it.
The difference between the two is at position 1: lysine in Prostamax, alanine in Cortagen. That single substitution adds a positive charge, which changes the peptide’s net charge, its interaction with negatively charged DNA, and its chromatographic behaviour. Whether it also confers the tissue selectivity claimed for it is exactly the open question, and it is testable by running both peptides side by side in the same two cell types.
What can be measured, and what cannot
Because the proposed mechanism is transcriptional, the readouts that suit this compound are transcript and protein level rather than organ level. In a prostate epithelial model that means qPCR or RNA-seq, protein confirmation of any transcript hit, proliferation and viability assays, and where the question concerns inflammatory signalling, cytokine output measured directly rather than inferred. If reducing inflammation is your endpoint, measure the cytokines; prostate function, immune function and cellular repair are all phrases that describe outcomes at a level a dish cannot report on.
Two format notes. The peptide is supplied as a metered spray, which places it in the nasal cavity category by packaging rather than by pharmacology, and describing that format as non-invasive is a statement about the container rather than about how the compound behaves. Peptide therapy is likewise a clinical term that does not apply to research material. Neither the format nor the category label changes what this is: a research chemical for laboratory use.
Prostamax nasal spray specifications
| Compound |
Prostamax, synthetic short peptide bioregulator |
| Sequence |
Lys-Glu-Asp-Pro (KEDP) |
| Length |
Tetrapeptide (four residues) |
| Molecular formula |
C20H33N5O9 |
| Molecular weight |
Approximately 487.5 Da |
| Structural note |
C-terminal proline restricts backbone flexibility |
| Closest relative in range |
Cortagen (AEDP); differs only at position 1 |
| Origin |
St Petersburg Institute of Bioregulation and Gerontology |
| Proposed mechanism |
Peptide-DNA or peptide-histone interaction altering gene accessibility (hypothesis) |
| Evidence status |
Preclinical, largely Khavinson-school animal and cell-culture work; no Western randomized trials of synthetic KEDP |
| Regulatory status |
No FDA or EMA approval |
| Format |
Metered spray bottle |
| Classification |
Research chemical. In-vitro laboratory use only. Not for human or veterinary use. |
What the evidence supports
The mechanistic proposal for this class is that short peptides enter cells, reach the nucleus and interact with DNA promoter regions or chromatin-associated histones, altering which genes are accessible to transcription factors. The general argument appears in Short Peptides Regulate Gene Expression in the Bulletin of Experimental Biology and Medicine, supported by mobility shift assays, histone binding assays and docking models.
For Prostamax specifically the published work is largely animal and cell-culture research from the Khavinson school, and there are no Western randomized controlled trials of the synthetic KEDP peptide. High-resolution structural confirmation of a peptide-DNA complex is unpublished for any member of this series. That is a thin evidence base, which is why this page is sized to it rather than padded, and why it makes no claim about any prostate condition.
Prostamax nasal spray storage and handling
KEDP contains no cysteine, no methionine and no tryptophan, so disulfide chemistry, oxidation and light sensitivity are not the practical risks. Charge and enzymatic exposure are.
With a lysine and two acidic residues, the peptide carries both positive and negative charge, so solubility and behaviour shift with pH and buffer control matters more than it appears to. A four-residue peptide is a ready substrate for serum peptidases, so long incubations in serum-containing medium give a declining exposure. Sensible prostamax nasal spray storage is otherwise routine: cold, sealed, out of light, single-use aliquots rather than repeated freeze-thaw on one container, and low-binding plasticware at low working concentrations.
How research grade prostamax spray is characterized
A short peptide carrying both basic and acidic residues retains poorly on a standard reversed-phase column, so the analytical method behind a purity figure is more informative than the figure itself. Hydrophilic interaction chromatography, ion-pairing or ion exchange paired with mass spectrometry suits a molecule like this, and mass confirmation near 487.5 Da is straightforward. A research grade prostamax spray is supplied under the same verification PrymaLab applies across its research peptides, HPLC and MS confirmation plus independent third-party testing. No specific lot figures are asserted here; request the certificate of analysis for the lot you receive and read the method line alongside the number.
For related bioregulator research, see the PrymaLab Research Library.
Frequently asked questions
What is Prostamax?
Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP), approximately 487.5 Da, one of the Khavinson-class short peptide bioregulators associated with prostate tissue in that framework. Material supplied here is a research chemical for in-vitro laboratory use only.
Which prostate cell line should be used?
It depends entirely on the question. LNCaP expresses androgen receptor and is required for androgen-related work, though its receptor is mutated with broadened ligand specificity. PC-3 and DU145 lack functional androgen receptor. All three are carcinoma lines, so none models normal prostate epithelium.
What models normal prostate epithelium?
Primary prostate epithelial cells or an immortalized non-tumorigenic line such as RWPE-1. For a compound framed around maintaining normal tissue gene expression, testing in an aggressive carcinoma line changes the question being asked.
How does Prostamax differ from Cortagen?
Only at position 1: Prostamax is Lys-Glu-Asp-Pro, Cortagen is Ala-Glu-Asp-Pro. The lysine adds a positive charge, changing net charge and chromatographic behaviour. Whether it confers the different tissue association claimed for them is testable by running both in the same cell types.
Is Prostamax nasal spray approved for human use?
No. This material is a research chemical for in-vitro laboratory use only, has no FDA or EMA approval, and is not intended for human or veterinary use. No claim is made here regarding any prostate condition. Nothing here is medical advice.
Ordering and compliance
Every PrymaLab research compound ships from the United States and is sold research-use-only. This prostamax peptide nasal spray is supplied for in-vitro laboratory research, is not intended for human or veterinary use, is not a drug or supplement, and has not been evaluated by the FDA for the research-chemical context. Verify the legal status of any research compound in your jurisdiction before ordering. Certificates of analysis are available on request for the lot you receive.
5 reviews for Prostamax 20mg Nasal Spray